Guangdong Hybribio Biotech (SHE:300639) subsidiary Guangzhou Kaipu Pharmaceutical Technology will conduct clinical trials on chloroquine phosphate gel after receiving approval from China's National Medical Products Administration, a Saturday filing on the Shenzhen Stock Exchange said.
The drug will be tested as a treatment for patients with human papillomavirus.
Price (RMB): ¥5.06, Change: ¥+0.020, Percent Change: +0.40%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.